Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Urology
  • Urology News
  • Intake of 5-ARIs for...

Intake of 5-ARIs for BPH not associated with increased mortality in prostate cancer

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2022-06-07T19:30:00+05:30  |  Updated On 7 Jun 2022 2:00 PM GMT
Intake of 5-ARIs for BPH not associated with increased mortality in prostate cancer

Researchers have found in a new study that Intake of 5-ARIs for BPH is not associated with increased mortality in prostate cancer. The study has been published in the journal of American Medical Association."Our results indicate that 5-ARIs are safe to use regarding the risk of prostate cancer, and we hope that this study will alleviate concerns and allow for better access to these drugs for...

Researchers have found in a new study that Intake of 5-ARIs for BPH is not associated with increased mortality in prostate cancer. The study has been published in the journal of American Medical Association.

"Our results indicate that 5-ARIs are safe to use regarding the risk of prostate cancer, and we hope that this study will alleviate concerns and allow for better access to these drugs for men suffering from lower urinary symptoms caused by benign prostate hyperplasia", says Lars Björnebo, first author of the study and PhD Candidate at the Department of Medical Biostatistics and Epidemiology.

A previous study from the same research group published in 2018 found a decrease in diagnosed prostate cancer for men treated with 5-ARI. "We wanted to assess whether our previous results had an implication for mortality in prostate cancer, says Anna Lantz, senior author and Associate Professor at Karolinska Institutet.

Two large randomized controlled trials, PCPT and REDUCE, performed to assess whether 5-ARIs could be used to prevent prostate cancer found an overall lower risk of prostate cancer in men treated with the drug. However, both trials also found an increased rate of more aggressive forms of prostate cancer.

These findings were later attributed to increased sensitivity of PSA and biopsies for men treated with the drugs. Nevertheless, it subsequently led to a hesitancy to prescribe the medications and a warning from the US Food and Drug Administration, which was later withdrawn.Since then, many observational studies have been published with varying results concerning the risk of developing and dying from prostate cancer in men treated with 5-ARIs. The long-term follow-up of the randomized trials has not shown any increased risk of dying from prostate cancer in men treated with 5-ARIs.

This large population-based cohort study included 349 152 men, with 26 190 men receiving Finasteride or Dutasteride during the study period between 2007 and 2018. By linking multiple Swedish registries, the researchers were able to adjust for numerous confounders and ensure that the included men were free from prostate cancer and 5-ARI treatment at the start of the study. "This is the first observational study considering 5-ARIs and prostate cancer mortality in men without a previous diagnosis of prostate cancer, which is essential for studying this association", says Lars Björnebo.

The study saw no increased risk of dying from prostate cancer for men treated with 5-ARIs, but a decreased risk after longer treatment durations. A higher frequency of testing for prostate cancer with both PSA and biopsies was also observed in the men treated with 5-ARIs.

"We cannot say definitively whether the drug, increased testing or something else is causing the decrease in prostate cancer mortality," says Lars Björnebo. "We do not believe further clinical trials with these drugs are beneficial. Our main message is that these drugs are safe to use as intended."

JAMA Oncology 5-ARIs BPH prostate cancer cancer hyperplasia drugs PSA Food and Drug Administration FDA 
Source : JAMA Oncology
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X